Genient Technologies Partners with Aabir Bio-Services Foundation to Advance Women’s Health and Cervical Cancer Elimination

Genient Technologies has signed a Memorandum of Understanding (MoU) with Aabir Bio-Services Foundation, a not-for-profit organization committed to advancing women’s health through HPV awareness, education, and research. This strategic collaboration marks a significant step toward supporting India’s Cervical Cancer Elimination by 2030 mission.

Through this partnership, Genient and Aabir Bio-Services Foundation will work together to strengthen early detection and prevention of cervical cancer by advancing:

• HPV DNA and RNA–based screening initiatives
• DeepChek® Assay HPV messenger RNA genotyping and variant surveillance
• Capacity building through training programs and public-health outreach
• Collaborative research aligned with national and global cervical cancer control strategies

The collaboration aims to integrate advanced genomic technologies with community-level education and implementation, ensuring that precision diagnostics translate into real-world impact for women’s health.

"Our vision is a cervical-cancer-free India — made possible by genomic innovation, education, and collaboration,” said Genient Technologies.

This initiative aligns with global scientific progress in HPV research, including recent international collaborations focused on next-generation HPV RNA sequencing. Such science-led partnerships reinforce the role of innovation and cooperation in delivering accessible, affordable, and actionable precision healthcare

The DeepChek® Assay HPV messenger RNA Genotyping represents a cutting-edge research approach that enhances HPV screening by identifying high-risk viral strains, assessing oncogenic activity, and supporting risk stratification for progression to cervical cancer. By combining advanced diagnostics with outreach and education, Genient and Aabir Bio-Services Foundation aim to accelerate meaningful progress in women’s health and public-health outcomes.